CD5 and acute lymphoblastic leukemia: In a clinical study (NCT03081910), TKI-pretreated CD5 CAR-T cells showed more sustained persistence in patients, and four of seven patients with R/R T-ALL achieved minimal residual disease (MRD)-negative CR [9].